news
TxCell reacquires full rights to Ovasave from Trizell
3 December 2015 | By Victoria White
TxCell has agreed with Trizell to terminate the collaboration, option, development and license agreement concerning TxCell’s lead product Ovasave...
List view / Grid view
TxCell
news
MaSTherCell to manufacture TxCell’s lead product Ovasave
29 July 2015 | By Victoria White
TxCell and MaSTherCell have signed a Memorandum of Understanding for the manufacturing by MaSTherCell of clinical batches of TxCell’s Ovasave...
news
TxCell appoints Stéphane Boissel as Chief Executive Officer and promotes Miguel Forte to Chief Operating Officer
28 April 2015 | By Victoria White
TxCell has appointed Stéphane Boissel as CEO. In addition, Dr. Miguel Forte, previously SVP Clinical and Regulatory, has been promoted to COO...
news
TxCell and Trizell amend agreement to accelerate Ovasave development
24 April 2015 | By Victoria White
TxCell has announced an amendment to the Ovasave collaboration option, development and license agreement (Ovasave Agreement) with Trizell...
news
TxCell to present at EU Advanced Therapies Investor Day November 13, in London, UK
7 November 2014 | By TxCell
TxCell SA announces that Damian Marron, CEO, TxCell, will present at the 2nd Annual EU Advanced Therapies Investor Day in London...
news
TxCell reports revenues for the third quarter of 2014
5 November 2014 | By TxCell
TxCell (FR0010127662 - TXCL), a biotechnology company developing innovative, economically viable, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today reports its revenues(1) as of September 30, 2014...
news
Clinical trial success for Crohn’s Disease cell therapy
30 March 2011 | By UK National Stem Cell Network (UKNSCN)
Professor Miguel Forte will describe research into a new cell therapy at the UK National Stem Cell Network annual science meeting...
